Sector News

Valeant posts 36% growth amid pricing scrutiny; may sell neurology biz

October 19, 2015
Life sciences

Valeant may be the subject of current government scrutiny, and it may have recently suffered a stock-price freefall. But the company gave investors some good news Monday with earnings that beat their mark.

The Canadian drugmaker recorded third-quarter EPS of $2.74, excluding one-time items–topping consensus estimates of $2.70. Revenue also ticked upward by 36% year-over-year, hitting $2.79 billion, partly thanks to recent acquisition Salix, which delivered $461 million–almost 50% more than the $300 million Valeant had forecast.

And another high point for the Quebec-based pharma: The growth was more volume than price, if by a small margin. Evercore ISI analyst Umer Raffat noted that in the U.S., 19% of Valeant’s branded prescription product growth was driven by volume increases, compared with 15% from price increases.

Those price increases have put Valeant in the hot seat recently, with lawmakers demanding information on the company’s strategy, particularly on a couple of large–and highly publicized–increases. Last week, Valeant revealed that it had received subpoenas from the U.S. Attorney’s Office for the District of Massachusetts and from the U.S. Attorney’s Office for the Southern District of New York, requesting materials largely related to its pricing decisions.

CEO J. Michael Pearson has maintained that hiking prices–which Valeant has done 56 times this year alone–isn’t a key facet of the company’s broader strategy. As he outlined Monday on a conference call, the company has other moves up its sleeve to keep business booming.

For one, it may hive off its neurology and “other” drugs business, he told investors, a non-core unit that would make up about 10% of future sales.

“Given the current environment, I think that it probably doesn’t make sense for us to hold on to it,” he said, as quoted by Bloomberg. “Hopefully we’ll figure out a way to do it in a way that shareholders can continue to participate in an entity that’s maybe not a growth company, but a big dividend company.”

Valeant also plans to sock more money into R&D, an area where it’s traditionally been averse to spending. Instead, it’s thrown its weight behind acquisitions–and it’ll continue to do so, though with different criteria.

“It’s likely we’ll pursue fewer if any transactions that are focused on mispriced products,” Pearson said on the call.

Instead, the company will be seeking “durable” assets that would fit with its Bausch + Lomb eyecare business, which it picked up back in 2013, Reuters reports.

In the meantime, Valeant expects sales to keep expanding. It raised its Q4 forecast slightly, to a range of $3.25 billion to $3.45 billion, up from $3.2 billion to $3.4 billion. On the adjusted EPS side, the company now predicts it’ll land between $4 to $4.20, boundaries it ticked upward from an earlier $3.98 to $4.18 forecast.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.